Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 67577R102 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Caligan Partners LP
13G/A
Amendment 1
|
7.3% |
8/14/2026
Event 6/30/2026
|
|
| Caligan Partners LP | 7.3% | ||
| Johnson David Edward | 7.3% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 3
|
10.0% |
8/14/2026
Event 6/30/2026
|
|
| Perceptive Advisors LLC | 10.0% | ||
| Joseph Edelman | 10.0% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||
|
Balyasny Asset Management L.P.
13G/A
Amendment 2
|
6.6% |
8/14/2026
Event 6/30/2026
|
|
| Balyasny Asset Management L.P. | 6.6% | ||
| Bam GP LLC | 6.6% | ||
| Balyasny Asset Management Holdings LP | 6.6% | ||
| Dames GP LLC | 6.6% | ||
| Dmitry Balyasny | 6.6% | ||
|
Foundation Fighting Blindness Retinal Degeneration Fund
13D/A
Amendment 3
|
4.7% |
5/20/2026
Event 5/18/2026
|
|
| Foundation Fighting Blindness Retinal Degeneration Fund | 4.7% | ||
| Foundation Fighting Blindness, Inc. | 4.7% | ||
|
Caligan Partners LP
13G
|
8.5% |
5/15/2026
Event 3/31/2026
|
|
| Caligan Partners LP | 8.5% | ||
| Johnson David Edward | 8.5% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 2
|
10.0% |
5/15/2026
Event 3/31/2026
|
|
| Perceptive Advisors LLC | 10.0% | ||
| Joseph Edelman | 10.0% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||
|
Balyasny Asset Management L.P.
13G/A
Amendment 1
|
7.2% |
5/15/2026
Event 3/31/2026
|
|
| Balyasny Asset Management L.P. | 7.2% | ||
| Bam GP LLC | 7.2% | ||
| Balyasny Asset Management Holdings LP | 7.2% | ||
| Dames GP LLC | 7.2% | ||
| Dmitry Balyasny | 7.2% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 3
|
6.5% |
5/15/2026
Event 3/31/2026
|
|
| Nantahala Capital Management, LLC | 6.5% | ||
| Wilmot B. Harkey | 6.5% | ||
| Daniel Mack | 6.5% | ||
|
BIOS Fund III, LP
13G/A
Amendment 2
|
4.5% |
5/13/2026
Event 5/12/2026
|
|
| Aaron G.L. Fletcher | 4.5% | ||
| Bios Advisors GP, LLC | 4.5% | ||
| Bios Capital Management, LP | 4.5% | ||
| Bios Equity Partners III, LP | 4.5% | ||
| Bios Fund III, LP | 0.5% | ||
| Bios Fund III NT, LP | 0.6% | ||
| Bios Fund III QP, LP | 3.4% | ||
| Cavu Advisors, LLC | 4.5% | ||
| Cavu Management, LP | 4.5% | ||
| Leslie W. Kreis | 4.5% | ||
|
Adage Capital Management, L.P.
13G
|
8.5% |
5/13/2026
Event 3/31/2026
|
|
| Adage Capital Management, L.P. | 8.5% | ||
| Robert Atchinson | 8.5% | ||
| Phillip Gross | 8.5% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 1
|
10.0% |
2/17/2026
Event 12/31/2025
|
|
| Perceptive Advisors LLC | 10.0% | ||
| Joseph Edelman | 10.0% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||
|
Balyasny Asset Management L.P.
13G
|
7.4% |
2/17/2026
Event 12/31/2025
|
|
| Balyasny Asset Management L.P. | 7.4% | ||
| Bam GP LLC | 7.4% | ||
| Balyasny Asset Management Holdings LP | 7.4% | ||
| Dames GP LLC | 7.4% | ||
| Dmitry Balyasny | 7.4% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 2
|
10.0% |
2/13/2026
Event 12/31/2025
|
|
| Nantahala Capital Management, LLC | 10.0% | ||
| Wilmot B. Harkey | 10.0% | ||
| Daniel Mack | 10.0% | ||
|
Foundation Fighting Blindness Retinal Degeneration Fund
13D/A
Amendment 2
|
8.0% |
12/11/2025
Event 12/9/2025
|
|
| Foundation Fighting Blindness Retinal Degeneration Fund | 8.0% | ||
| Foundation Fighting Blindness, Inc. | 8.0% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 1
|
10.0% |
8/14/2025
Event 6/30/2025
|
|
| Nantahala Capital Management, LLC | 10.0% | ||
| Wilmot B. Harkey | 10.0% | ||
| Daniel Mack | 10.0% | ||
|
Nantahala Capital Management, LLC
13G
|
10.0% |
5/15/2025
Event 3/31/2025
|
|
| Nantahala Capital Management, LLC | 10.0% | ||
| Wilmot B. Harkey | 10.0% | ||
| Daniel Mack | 10.0% | ||
|
Foundation Fighting Blindness Retinal Degeneration Fund
13D/A
Amendment 1
|
15.9% |
5/6/2025
Event 4/30/2025
|
|
| Foundation Fighting Blindness Retinal Degeneration Fund | 15.9% | ||
| Foundation Fight Blindness, Inc. | 15.9% | ||
|
Perceptive Advisors LLC
13G
|
10.0% |
3/31/2025
Event 3/24/2025
|
|
| Perceptive Advisors LLC | 10.0% | ||
| Joseph Edelman | 10.0% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 4.92 k | $23.8 k |
| 2026 Q2 | 107 | 60.6 M | $250 M |
| 2026 Q1 | 81 | 45.4 M | $204 M |
| 2025 Q4 | 60 | 27.8 M | $55.9 M |
| 2025 Q3 | 48 | 19.0 M | $31.9 M |
| 2025 Q2 | 46 | 17.6 M | $16.6 M |
| 2025 Q1 | 49 | 14.6 M | $14.7 M |
| 2024 Q4 | 46 | 3.68 M | $4.38 M |
| 2024 Q3 | 41 | 2.53 M | $3.32 M |
| 2024 Q2 | 40 | 2.75 M | $4.21 M |
| 2024 Q1 | 54 | 3.52 M | $7.08 M |
| 2023 Q4 | 54 | 3.77 M | $11.3 M |
| 2023 Q3 | 52 | 3.77 M | $12.6 M |
| 2023 Q2 | 54 | 3.68 M | $16.0 M |
| 2023 Q1 | 44 | 3.46 M | $13.0 M |
| 2022 Q4 | 39 | 3.16 M | $11.1 M |
| 2022 Q3 | 40 | 2.83 M | $5.69 M |
| 2022 Q2 | 41 | 2.41 M | $4.62 M |
| 2022 Q1 | 45 | 2.07 M | $6.69 M |
| 2021 Q4 | 51 | 2.23 M | $8.31 M |
| 2021 Q3 | 37 | 1.68 M | $8.62 M |
| 2021 Q2 | 40 | 1.07 M | $5.61 M |
| 2021 Q1 | 29 | 912 k | $5.27 M |
| 2020 Q4 | 15 | 2.21 M | $14.5 M |